Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

(currently amended) A pharmaceutical composition comprising an agent
effective to elicit an immunogenic response to alpha-synuclein and an adjuvant that is
pharmaceutically acceptable for human administration, wherein the adjuvant is selected from the
group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF, wherein the
agent is alpha-synuclein or an immunogenic fragment thereof.

(cancel)

- (currently amended) The pharmaeeutical composition of claim 2, wherein the agent is alpha-synuclein.
- (currently amended) The pharmaceutical composition of claim 2, wherein the agent is immunogenic alpha-synuclein fragment.
- (currently amended) The pharmaceutical composition of claim 4, wherein the agent is NAC.
- (currently amended) The composition of any one of claims 1-5, wherein
 the agent is linked to a carrier molecule to form a conjugate. pharmaceutical

7-8. (canceled)

9. (currently amended) A pharmaceutical composition comprising an agent effective to elicit an immunogenic response against an alpha-synuclein component of an amyloid plaque in a patient and an adjuvant that is pharmaceutically acceptable for human administration wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF. Appl. No. 10/698,099 Amdt. dated July 8, 2008 Reply to Office Action of January 8, 2008

- (currently amended) The pharmaceutieal composition of claim 9, wherein the agent is alpha-synuclein or an immunogenic alpha-synuclein fragment.
- (currently amended) The pharmaceutical composition of claim 9, wherein the agent is alpha-synuclein.
- (currently amended) The pharmaceutical composition of claim 9, wherein the agent is an immunogenic alpha-synuclein fragment.
- (currently amended) The pharmaceutical composition of claim 12, wherein the immunogenic alpha-synuclein fragment is NAC.
 - 14-53. (canceled)
- (currently amended) The composition of claim 1, manufactured under good manufacturing <u>practice</u> conditions.
- 55. (previously presented) The composition of claim 1, wherein the agent is filter sterilized.